VBI Vaccines Competitors and Similar CompaniesClear all

VBI Vaccines's competitors and similar companies include PolyPid, Metabolon, Adaptimmune and CosmosID.

	VBI Vaccines VBI Vaccines is a biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.	PolyPid PolyPid is a company developing a technology platform that enables a controlled and prolonged release of active pharmaceutical ingredients (API).	Metabolon Global leader in metabolomics for precision medicine, biomarker discovery, and advancing pharma & life sciences research.	Adaptimmune Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.	CosmosID CosmosID develops softwarefor identifyingpathogens present in clinical, environmental, and other research samples.
Founding Date	Founding Date 2001	Founding Date 2008	Founding Date 2000	Founding Date 2008	Founding Date 2008
Type	Type Public	Type Public	Type Private	Type Public	Type Private
Tags	Tags Healthcare Technology biotech healthtech pharma	Tags Healthcare Technology biotech healthtech pharma	Tags Healthcare Technology biotech healthtech pharma	Tags Healthcare Technology biotech healthtech pharma	Tags Healthcare Technology biotech fitness & wellness healthtech pharma
Locations	Locations Cambridge, US HQ Ottawa, CA Rehovot, IL	Locations Petah Tikva, IL HQ Summit, US	Locations Morrisville, US HQ Hallbergmoos, DE München, DE	Locations Philadelphia, US HQ Milton, GB Milton, GB Stevenage, GB	Locations Germantown, US HQ Södertälje, SE
Employees	Employees 12314% increase	Employees 57	Employees 1911% increase	Employees 4007% decrease	Employees 254% decrease
Valuation ($)	Valuation ($) 1.9 m	Valuation ($) 23.7 m	Valuation ($) N/A	Valuation ($) 188.5 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $8.7m (FY, 2023)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $178m (FY, 2024)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $70k (FY, 2024)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit $178m (FY, 2024)	Gross profit N/A
Net income	Net income ($92.8m) (FY, 2023)	Net income ($29m) (FY, 2024)	Net income N/A	Net income ($70.8m) (FY, 2024)	Net income N/A
Operating ⚠
Patent Applications	Patent Applications N/A	Patent Applications 49 (FY, 2017)	Patent Applications N/A	Patent Applications 69 (FY, 2016)	Patent Applications N/A
Patents Issued	Patents Issued N/A	Patents Issued 104 (FY, 2017)	Patents Issued N/A	Patents Issued 173 (FY, 2016)	Patents Issued N/A
Funding
Latest funding round	Latest funding round N/A	Latest funding round N/A	Latest funding round $ 15m (over 8 years ago)	Latest funding round N/A	Latest funding round $ 6m (over 9 years ago)
Total funding raised	Total funding raised N/A	Total funding raised $ 103.8m	Total funding raised $ 95.4m	Total funding raised $ 107.5m	Total funding raised $ 7.2m